GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sanara MedTech Inc (NAS:SMTI) » Definitions » Shares Outstanding (Diluted Average)

Sanara MedTech (Sanara MedTech) Shares Outstanding (Diluted Average) : 8.38 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Sanara MedTech Shares Outstanding (Diluted Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Sanara MedTech's average diluted shares outstanding for the quarter that ended in Dec. 2023 was 8.38 Mil.


Sanara MedTech Shares Outstanding (Diluted Average) Historical Data

The historical data trend for Sanara MedTech's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanara MedTech Shares Outstanding (Diluted Average) Chart

Sanara MedTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (Diluted Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.57 5.74 7.34 7.91 8.28

Sanara MedTech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shares Outstanding (Diluted Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.12 8.17 8.23 8.33 8.38

Sanara MedTech Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Sanara MedTech  (NAS:SMTI) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Sanara MedTech Shares Outstanding (Diluted Average) Related Terms

Thank you for viewing the detailed overview of Sanara MedTech's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Sanara MedTech (Sanara MedTech) Business Description

Traded in Other Exchanges
N/A
Address
1200 Summit Avenue, Suite 414, Fort Worth, TX, USA, 76102
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser and BIAKOS Skin and Wound Gel.
Executives
Eric D Major director 751 MILLER DRIVE SE, LEESBURG VA 20175
Zachary B. Fleming officer: President - Surgical Div. 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Shawn M. Bowman officer: President - Wound Care Div. 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Rebecca E Mcmahon officer: President - R&D 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Sara N Ortwein director 5959 LAS COLINAS BOULEVARD, IRVING TX 75039-2298
Robert Andrew Desutter director 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Eric D Tanzberger director 1929 ALLEN PARKWAY, HOUSTON TX 77219
Christopher A. Morrison officer: President - Telehealth Svcs. 1200 SUMMIT AVENUE, SUITE 414, FORT WORTH TX 76102
Roszell Iii Mack director 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Cgi Cellerate Rx, Llc 10 percent owner C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
Catalyst Rochal, Llc 10 percent owner C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
Bradley J. Gurasich 10 percent owner C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
J Michael Carmena director, officer: Principal Executive Officer 1200 SUMMIT AVE STE 414, FORT WORTH TX 76102
Michael D. Mcneil officer: Chief Financial Officer 1200 SUMMIT AVE, STE 414, FORT WORTH TX 76102
Catalyst Group, Inc. 10 percent owner 1375 ENCLAVE PARKWAY, HOUSTON TX 77077

Sanara MedTech (Sanara MedTech) Headlines

From GuruFocus

InfuSystem and Sanara MedTech Announce Wound Therapy Partnership

By Business Wire Business Wire 11-03-2022

Sanara MedTech Inc. Announces First Quarter 2022 Results

By GuruFocusNews GuruFocusNews 06-05-2022

Sanara MedTech Inc. Announces First Quarter 2022 Results

By PurpleRose PurpleRose 07-15-2022

Sanara MedTech Inc. Announces First Quarter 2022 Results

By GuruFocusNews GuruFocusNews 06-15-2022

Sanara MedTech Inc. Announces First Quarter 2023 Results

By sperokesalga sperokesalga 05-15-2023

Sanara MedTech Inc. Announces Third Quarter 2022 Results

By Value_Insider Value_Insider 11-14-2022

Sanara MedTech and InfuSystem Announce Wound Therapy Partnership

By Value_Insider Value_Insider 11-03-2022